Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 63.42M P/E - EPS this Y 31.40% Ern Qtrly Grth -
Income -30.16M Forward P/E -2.45 EPS next Y 66.70% 50D Avg Chg -19.00%
Sales 2.81M PEG - EPS past 5Y - 200D Avg Chg -26.00%
Dividend N/A Price/Book 12.67 EPS next 5Y - 52W High Chg -48.00%
Recommedations 2.40 Quick Ratio 0.56 Shares Outstanding 100.58M 52W Low Chg 4.00%
Insider Own 1.65% ROA -59.02% Shares Float 98.89M Beta 1.21
Inst Own 6.60% ROE -994.69% Shares Shorted/Prior 246.91K/456.20K Price 0.74
Gross Margin - Profit Margin - Avg. Volume 273,682 Target Price 4.67
Oper. Margin -274.99% Earnings Date May 9 Volume 380,742 Change 0.68%
About Dare Bioscience, Inc.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Dare Bioscience, Inc. News
04/23/24 Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
04/11/24 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
04/01/24 Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript
03/29/24 Q4 2023 Dare Bioscience Inc Earnings Call
03/28/24 Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
03/21/24 Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
02/22/24 Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
01/31/24 Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
04:30 PM Daré Bioscience Announces Executive Team and Board of Directors Changes
01/17/24 Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
01/04/24 Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
01/04/24 When Will Daré Bioscience, Inc. (NASDAQ:DARE) Become Profitable?
08:00 AM Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
12/20/23 Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
12/13/23 Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
12/07/23 Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause
12/04/23 Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
11/23/23 20 Countries with the Highest Teenage Pregnancy Rates
11/20/23 Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs
11/13/23 Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting
DARE Chatroom

User Image Guy592 Posted - 2 hours ago

$DARE if you're not riding with Sabrina now, then don't ride with her when we're up. All sour so-called investors. As if Sabrina promised you a certain price at a certain time. No fools, we all decided to throw money in an investment. Nothing was guaranteed. I'm down and have high hopes. I'll ride it until there's a road block.

User Image Guy592 Posted - 5 hours ago

$DARE next week, we slapping the ask. Hard like we stomping on 🪳

User Image Guy592 Posted - 8 hours ago

$DARE You're not shorting, cockroach. You're not making money. All you do is post fud and like it yourself. LOL What pathetic creature are you? Get a life!

User Image Guy592 Posted - 8 hours ago

$DARE praying for the ceo to sell the company in 2022 for $5 is not a good business model, cockroach. Look how you try to use your fud. "Two top executives scurried for the exit." LOL. Pathetic 🪳.

User Image Punted Posted - 8 hours ago

$DARE praying for government welfare is not a business model or plan for success. products soooooo good they with dare Bioscience…think about that for a long second. call themselves ”leaders in womens health” based on? Lol a BV drug no one asked for. not preferred. zero reviews to be found online. joke, like this company!

User Image Punted Posted - 8 hours ago

$DARE two top officer scurried for the exit, but not with out sweet parachutes. xaciato royalties mostly gone for a bad bad loan. Negative working capital. only 1 product being studied. expects to complete fall 2025, how long for topline data? fda submission 2027? precious capital gone because they couldnt be bothered to verify an invoice. accounting firm quit two months after shareholders voted to hire. negative working capital but they still take the ”team” to new orleans. dilution dilution dilution. lots more but you get the drift, do your DD

User Image Guy592 Posted - 9 hours ago

$DARE -Two top employees resign instead of doing a rs. -The company's presentation slides were taken down. -An extension/exception was granted by NASDAQ for compliance. -$200 million shelf offering filed. - Government $100 million women's initiative launched. -Xaciato first real sales next month. -Ovaprene phase 3 in progress. I'm missing a lot more but I'll leave it here. There is so much positive from the company, but yet ppl trash Sabrina.

User Image Guy592 Posted - 9 hours ago

$DARE

User Image Guy592 Posted - 12 hours ago

$DARE 7 years later, Bayer and the NIH are so in love with Ovaprene. Money stacked in it. Let's go, Ovaprene! Bring that baby to market, Sabrina.

User Image Punted Posted - 12 hours ago

$DARE ovaprene gonna be such a big hit. lets recap that ”products” history. in 2010 it finished phase 2. yep 14 years ago. dare got its paws on it in 2017…seven years NO ONE wanted it. in 7 years dare did a safety and acceptability study on 30 sterile women and it took YEARS to release the results. lol all the ear marks of a homerun! https://www.biospace.com/article/releases/ovatech-inc-closes-successful-phase-2-birth-control-trial-/?keywords=Partner

User Image Guy592 Posted - 12 hours ago

$DARE Make sure you guys have a social life. I know most of us are invested here. The others are just losers wasting their time. Pathetic broke 🪳

User Image Punted Posted - 13 hours ago

$DARE 😂 make sure youre getting your votes in for that RS! dont make her have to adjourn and twist arms like when you voted for that 240 mil authorized shareS! lol get out the vote!

User Image alejajcucha Posted - 14 hours ago

$DARE is she still the CEO?!?!?! Get someone else. Please!!! 🚀🚀🚀

User Image Punted Posted - 14 hours ago

$DARE seriously. what are 20+ people doing? they have just one product being studied…ONE! they cant be bothered to update the corporate presentation in nearly FOUR months! honest question…what are they being paid for? they all gettin bonuses for the failure that was last year. lol all while having negative working capital, selling off royalties…lol they gettin bonuses and trip to new orleans. Again, this is not a serious group of people.

User Image Mister_Moon Posted - 20 hours ago

$DARE Man, this thing is doing the limbo. How much lower will see go today. This is what you get when liars are employed by someone to pump, right, self proclaimed smartest schmuck on Stocktwits? You've said the lady was so transparent, so prudent, so forthcoming and open about development of the Company. She is silent now, and has been for a while. Where are you now, why is it so hard for you to be honest? It's easy being a good weather CEO, but the true ones shine through in bad weather. What is the status on that pipeline, be honest, forthcoming and inform us! Where is the money coming from, Lady?? How are you going to pay for progressing the pipeline?? Is a R/S in the books, do you need to dilute? Answers we need, not just a pretty face!

User Image BBWs_Fast_Food_Fund Posted - 1 day ago

$DARE Do you folks want this stock higher? Install this man as CEO and he will not disappoint. He’s cute (real cute). He’s innocent. He’s adorable. His smiles are contagious. And he has what it takes to get this stock higher* *Drugs are known to cause one to get high

User Image Guy592 Posted - 1 day ago

$DARE Wrong!!! LOL

User Image Tank_Abbott Posted - 1 day ago

$DARE how can people keep defending this stock? You have to stay aware of how bad this company has been for the past 2 plus years. So disappointing 😞

User Image Mister_Moon Posted - 1 day ago

$DARE Damn, I just wonder who's paying biotechfraud (I guess the same person as a character called BiotechCEO who used to frequent ST ..... but that profile somehow went up in smoke, much like the majority of Ray's accounts) and who was paying Ray

User Image TravisA9 Posted - 1 day ago

$DARE Needs large influx of cash that’s not tied to progressing pipeline activities. Bear thesis has been simple for well over a year here. Also, as a now commercialized company, enjoy the continued negative earnings sentiment around Xaciato revenues for quite a while.

User Image Guy592 Posted - 1 day ago

$DARE this Pos telling me I'm wrong when he was the one saying down in AH with a $20k sell. what a pathetic life

User Image Punted Posted - 1 day ago

$DARE for years bulls said this would run to $17.28. i said $.1728…..been right at every turn, but it dont stop the bulls from lying trying to get new bag holders to take there spot!

User Image Punted Posted - 1 day ago

$DARE biotechfraud….what PR’s are coming? all these positions being dumped and yet you continue to live in your own reality that they holding some mythical good news causing this to run. its literally insane what you are doing, and frankly immoral. reality is they are BROKE! so broke they had to sell off future royalties….you dont do that to bridge short term, thats desperation! this will RS or pink sheet. thats it. even if they RS do they meet all nasdaq requirements? to my knowledge no. matter of fact i think with every penny down the lack of shareholder equity is exacerbated. this company is in dire straights, all the flashing warning signs are there. you can chose to ignore, but stop lying to people.

User Image TheArsenal Posted - 1 day ago

$DARE All your BS has led you to carrying bags of a POS penny bio near all time lows and ready to split. Well done biofraud. Keep buying though. It will make the split and immediate dilution that much funnier.

User Image BiotechJedi1728 Posted - 1 day ago

$DARE We are done with the bs now. Hopefully the last clear out before a run next week. The real PRs are coming then, and then right into Q1 call the week after. Buckle up.

User Image alejajcucha Posted - 1 day ago

$DARE is she still diluting? Oh wait, first she needs to do R/S…. Fucking management 🚀🚀🚀

User Image SoccerPeter Posted - 1 day ago

$DARE Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 04-23-2024 Under the terms of the grant agreement, Daré may receive a total of up to approximately $49 million to support nonclinical development of DARE-LARC1. To date, Daré has received payments totaling approximately $28.3 million. Additional payments are conditioned on the program meeting specified development and reporting milestones.

User Image SoccerPeter Posted - 1 day ago

$DARE 👀🔥 Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 https://stkt.co/J1gUajIa

User Image Guy592 Posted - 1 day ago

$DARE

User Image Love_No_Hate Posted - 2 days ago

$DARE I am scared of delisting 😳😳 Any honest advice please ??

Analyst Ratings
Brookline Capital Hold Apr 17, 24
HC Wainwright & Co. Buy Apr 1, 24
HC Wainwright & Co. Buy Nov 10, 23
HC Wainwright & Co. Buy Aug 11, 23
HC Wainwright & Co. Buy Jul 13, 23
HC Wainwright & Co. Buy Jun 6, 23
HC Wainwright & Co. Buy May 22, 23
HC Wainwright & Co. Buy May 12, 23
HC Wainwright & Co. Buy Mar 31, 23